http://www.poet-technologies.com/poet-technologies-announces-the-appointment-of-two-new-directors/

David E. Lazovsky is the founder of Intermolecular (NASDAQ: IMI) and served as the company’s President and Chief Executive Officer and as a member of the board of directors from September 2004 to October 2014. Mr. Lazovsky has an in‐depth knowledge of the semiconductor industry, technology and markets. Mr. Lazovsky raised significant amounts of venture capital and other strategic private investments in Intermolecular’s initial public offering. Prior to founding Intermolecular, Mr. Lazovsky held several senior management positions at Applied Materials (NASDAQ: AMAT). From 1996 through August 2004, Mr. Lazovsky held management positions in the Metal Deposition and Thin Films Product Business Group where he was responsible for managing more than $1 billion in Applied Materials’ semiconductor manufacturing equipment business. From 2003 until 2004, Mr. Lazovsky managed key strategic accounts in Business Management where he worked closely with leading integrated circuit manufacturers to ensure Applied Materials was developing and providing cutting‐edge technology solutions. From 2002 until 2003, Mr. Lazovsky served as the Technology Program Manager for the Endura 2 Platform, Applied Materials’ flagship 300mm metal deposition platform. From 2000 until 2002, Mr. Lazovsky was based in Grenoble, France and served as Director of Business Management for the European region in the Metal Deposition Product Business Group. Previously, Mr. Lazovsky served as a Business Manager from 1997 to 2000, Account Product Manager from 1995 to 1997.

Mr. Lazovsky holds a B.S. in mechanical engineering from Ohio University and, as of March 31, 2014, held 41 pending or issued U.S. patents.

http://www.intermolecular.com/company

"Intermolecular’s mission is to redefine R&D for the semiconductor and clean energy sectors as they develop new generations of technology for the communications, consumer electronics, medical device, automotive, and entertainment industries. We help our partners accomplish practical, market-oriented goals faster, with higher ROI, so that unique new devices, processes and materials can quickly move into volume production.

Growing risks in R&D

Semiconductor and clean energy companies today are dependent upon innovation for growth; falling even one technology node behind an industry leader can be devastating. Concurrently, R&D in these innovation-oriented industries is increasingly high-risk, with many hurdles in the path of bringing differentiated products to market in a timely way. R&D costs have increased, but speed has not – traditional methods of R&D are simply inadequate.

Outstanding technology and intellectual resources

Intermolecular is redefining R&D with a combination of technology (the High Productivity Combinatorial platform) and the outstanding intellectual resources of our experienced multidisciplinary team. Our tools and methods enable rapid experimentation and device prototyping, and dramatically reduce the time needed to create and analyze experimental data. The end result of our customer engagements provides customers with differentiated, IP-protected technology that they control and commercialize to drive profits.

Putting proven technology to work

Our methods have been demonstrated for more than 15 years in the biotechnology and pharmaceutical industries. Now, Intermolecular’s innovative business model allows our methods to be leveraged in three ways: participation in a collaborative development program (CDP) with Intermolecular's team, purchase of our Tempus™ HPC integrated hardware and software platform, or licensing of IP developed and qualified by Intermolecular."